

Appendix

9th November 2021

Drug-microenvironment mapping reveals resistance mechanisms and prognostic patient subgroups in CLL

Peter-Martin Bruch , Holly A. R. Giles*, Carolin Kolb, Sophie A. Herbst, Tina Becirovic, Tobias Roider, Junyan Lu, Sebastian Scheinost, Lena Wagner, Jennifer Huellein, Ivan Berest, Mark Kriegsmann, Katharina Kriegsmann, Christiane Zgorzelski, Peter Dreger, Judith B. Zaugg, Carsten Müller-Tidow, Thorsten Zenz, Wolfgang Huber*, Sascha Dietrich**

* These authors contributed equally to this work.

Appendix Methods

Drug-stimulation profiling of samples treated with Ibrutinib, IL4 and AS1517499

The experiment in Appendix Fig. 11, was performed as detailed in the main methods (Sample preparation and drug-stimulation profiling), but with the following adjustments. 16 independent CLL PBMC samples were used and luminescence was read out using a Perkin Elmer EnSight.

ATAC sequencing

Peripheral blood was taken from 4 CLL patients and separated by Ficoll gradient (GE Healthcare), mononuclear cells were cryopreserved on liquid nitrogen. Samples were later thawed from frozen as previously described¹ and MACS sorted for CD19 positive cells (Miltenyi autoMACS®). The cells were resuspended in RPMI (GIBCO, Cat.No. 21875–034), with the addition of 2mM glutamine (GIBCO, Cat.No. 25030–24), 1% Pen/Strep (GIBCO, Cat.No. 15140–122) and 10% pooled, heat-inactivated and sterile filtered human type AB male off the clot serum (PAN Biotech, Cat.No. P40–2701, Lot.No:P–020317). 5ml of cell suspension was cultured in 6–well plates (Greiner Bio–One Cat.No. 657160). After thawing, cells were incubated at 37°C and 5% CO₂ for 6 hours in 0.2% DMSO. The final cell concentration was 2x10⁶ cells/ml. Cell viability and purity was assessed using FACS. All samples had a viability over 90% and over 95% of CD19+/CD5+/CD3– cells.

ATAC sequencing library generation

ATACseq libraries were generated as described previously². Cell preparation and transposition was performed according to the protocol, starting with 5x10⁴ cells per sample. Purified DNA was stored at –20°C until library preparation was performed. To generate multiplexed libraries, the transposed DNA was initially amplified for 5x PCR cycles using 2.5 µL each of 25 µM PCR Primer 1 and 2.5 µL of 25 µM Barcoded PCR Primer 2 (included in the Nextera index kit, Illumina, San Diego, CA, USA), 25 µL of NEBNext High-Fidelity 2x PCR Master Mix (New England Biolabs, Boston, Massachusetts) in a total volume of 50 µL. 5 µL of the amplified DNA was used to determine the appropriate number of additional PCR cycles using qPCR. Additional number of cycles was calculated through the plotting of the linear Rn versus cycle, and corresponds to one-third of the maximum fluorescent intensity. Finally, amplification was performed on the remaining 45 µL of the PCR reaction using the optimal number of cycles determined for each library by qPCR (max. 13 cycles in total). The amplified fragments were purified with two rounds of SPRI bead clean-up (1.4x). The size distribution of the libraries was assessed on Bioanalyzer with a DNA High Sensitivity kit (Agilent Technologies, Santa Clara, CA), concentration was measured with Qubit® DNA High Sensitivity kit in Qubit® 2.0 Fluorometer (Life Technologies, Carlsbad, CA). Sequencing was performed on NextSeq 500 (Illumina, San Diego, CA, USA) using 75bp paired-end sequencing, generating approx. 450 million paired-reads per run, with an average of 55 million reads per sample.

ATAC sequencing analysis of transcription factor activity in trisomy 12 CLL

Raw ATACseq data generated from our CLL samples were processed as described in Berest et al. 2019³, with the only exception that we did not use CG bias correction step. We then used analytical mode of diffTF with HOCOMOCO v10 database⁴ using the following parameters: minOverlap = 1; design formula = “~ Patient + trisomy 12 status”.

Patient ID	Sex	Treated before	IGHV status	Methylation Cluster	Del13q	Del11q	Trisomy 12	Del17p
Pat_001	f	1	U	LP	1	0	0	0
Pat_002	m	1	M	IP	1	0	0	0
Pat_003	m	0	M	HP	0	0	1	0
Pat_004	f	1	U	LP	0	1	0	0
Pat_005	m	0	U	LP	1	0	0	0
Pat_006	f	0	U	LP	0	0	0	0
Pat_007	f	0	M	HP	1	0	0	0
Pat_008	m	1	U	LP	1	0	0	0
Pat_009	m	1	U	LP	1	0	0	1
Pat_010	f	1	U	LP	1	0	0	1
Pat_011	f	0	U	NA	0	0	1	0
Pat_012	f	0	M	HP	1	0	0	0
Pat_013	f	1	U	IP	1	1	0	0
Pat_014	m	0	M	HP	0	0	0	0
Pat_015	m	0	M	HP	1	0	0	0
Pat_016	m	0	M	HP	1	0	0	0
Pat_017	m	0	M	NA	1	0	0	0
Pat_018	f	1	U	LP	1	1	0	0
Pat_019	m	0	M	HP	1	0	0	0
Pat_020	f	1	M	IP	1	0	0	0
Pat_021	m	0	U	LP	0	0	0	1
Pat_022	f	0	M	IP	0	0	1	0
Pat_023	f	0	M	HP	0	0	0	0
Pat_024	f	1	M	HP	0	0	0	1
Pat_025	m	0	M	IP	1	0	0	0
Pat_026	m	0	M	HP	1	0	0	0
Pat_027	f	0	M	HP	1	0	0	0
Pat_028	f	0	M	IP	1	0	0	0
Pat_029	f	0	M	HP	1	0	0	0
Pat_030	m	1	M	HP	1	0	0	0
Pat_031	m	0	M	HP	0	0	0	0
Pat_032	f	1	U	LP	1	1	0	0
Pat_033	m	1	U	IP	0	1	0	0
Pat_034	m	1	U	LP	0	1	0	0
Pat_035	m	0	M	HP	1	0	0	0
Pat_036	m	1	U	LP	1	1	0	1
Pat_037	f	1	U	IP	1	0	0	0
Pat_038	m	0	M	IP	1	0	0	0
Pat_039	m	1	M	HP	1	0	0	0
Pat_040	f	0	M	HP	0	0	0	0
Pat_041	f	1	U	LP	0	0	1	0
Pat_042	f	0	M	IP	1	1	0	0
Pat_043	f	0	M	HP	1	0	0	0
Pat_044	m	0	M	HP	1	0	0	0
Pat_045	m	0	U	LP	0	0	0	0
Pat_046	m	0	M	IP	0	0	1	0
Pat_047	m	0	M	HP	1	0	0	0
Pat_048	m	0	M	HP	1	0	0	0
Pat_049	f	0	M	IP	0	1	0	0
Pat_050	m	0	M	HP	0	0	1	0
Pat_051	m	0	M	NA	1	0	0	0
Pat_052	f	0	M	IP	1	0	0	0
Pat_053	m	1	U	LP	1	1	0	0
Pat_054	f	1	U	LP	0	1	0	0
Pat_055	m	1	U	LP	0	0	0	0
Pat_056	f	0	U	LP	NA	NA	NA	NA
Pat_057	f	0	M	HP	1	0	1	0
Pat_058	f	1	U	LP	0	0	0	0
Pat_059	m	0	M	HP	1	0	0	0
Pat_060	m	1	M	IP	1	0	0	1
Pat_061	m	0	U	LP	0	0	1	0

(continued)

Patient ID	Sex	Treated before	IGHV status	Methylation Cluster	Del13q	Del11q	Trisomy 12	Del17p
Pat_062	m	1	U	LP	1	1	0	0
Pat_063	f	0	U	LP	1	0	0	0
Pat_064	m	1	U	LP	1	1	0	1
Pat_065	m	0	U	LP	0	1	0	0
Pat_066	m	1	U	LP	1	1	0	0
Pat_067	f	0	M	HP	1	0	0	0
Pat_068	m	0	M	HP	1	0	0	0
Pat_069	m	1	M	HP	1	0	0	0
Pat_070	f	0	M	HP	0	0	0	0
Pat_071	f	0	U	LP	0	0	0	0
Pat_072	m	1	M	HP	0	0	1	0
Pat_073	f	0	U	LP	1	1	0	0
Pat_074	f	0	M	HP	0	0	0	0
Pat_075	f	0	M	HP	1	0	0	0
Pat_076	m	0	M	HP	1	0	0	0
Pat_077	f	0	U	NA	0	0	1	0
Pat_078	m	0	U	LP	0	0	0	0
Pat_079	m	0	M	HP	1	0	0	0
Pat_080	f	0	M	HP	0	0	0	0
Pat_081	m	0	M	HP	0	0	0	0
Pat_082	m	0	U	LP	0	0	0	0
Pat_083	m	0	M	HP	0	0	0	0
Pat_084	m	0	U	LP	0	0	1	0
Pat_085	m	0	M	HP	0	0	0	0
Pat_086	m	1	U	LP	1	1	0	0
Pat_087	m	0	M	IP	1	0	0	0
Pat_088	f	1	U	LP	1	0	0	1
Pat_089	m	0	M	HP	0	0	0	0
Pat_090	m	1	U	LP	0	0	1	0
Pat_091	m	1	M	NA	1	0	0	0
Pat_092	m	1	M	HP	0	0	0	0
Pat_093	m	0	M	HP	1	0	0	0
Pat_094	f	1	M	HP	0	0	0	0
Pat_095	m	1	U	LP	0	0	0	0
Pat_096	m	0	M	HP	0	0	0	0
Pat_097	f	1	U	LP	0	0	0	0
Pat_098	m	0	M	HP	1	0	0	0
Pat_099	f	0	U	LP	1	0	0	0
Pat_100	f	0	U	LP	1	0	0	0
Pat_101	f	0	U	LP	1	0	0	0
Pat_102	m	1	U	IP	0	0	0	0
Pat_103	f	0	M	HP	1	0	1	0
Pat_104	f	1	M	HP	0	0	0	0
Pat_105	m	0	U	LP	NA	NA	NA	NA
Pat_106	m	0	U	LP	1	1	0	1
Pat_107	f	0	M	NA	1	0	0	0
Pat_108	m	0	M	NA	1	0	1	0
Pat_109	m	0	M	HP	1	0	0	0
Pat_110	m	0	M	IP	1	1	0	0
Pat_111	f	1	U	LP	1	0	0	0
Pat_112	f	0	M	NA	0	0	1	0
Pat_113	f	0	M	HP	1	0	0	0
Pat_114	m	0	U	LP	1	0	0	0
Pat_115	m	1	U	LP	1	0	0	1
Pat_116	m	0	U	LP	1	0	0	0
Pat_117	m	0	U	IP	1	0	0	0
Pat_118	f	0	M	HP	0	0	0	1
Pat_119	m	0	U	LP	NA	NA	NA	NA
Pat_120	f	0	U	LP	0	0	1	0
Pat_121	m	0	U	LP	0	0	0	1

(continued)

Patient ID	Sex	Treated before	IGHV status	Methylation Cluster	Del13q	Del11q	Trisomy 12	Del17p
Pat_122	m	0	U	LP	0	1	0	0
Pat_123	m	0	U	LP	1	0	0	1
Pat_124	f	0	M	HP	1	0	1	0
Pat_125	f	0	M	HP	1	0	0	0
Pat_126	m	1	NA	NA	0	0	1	0
Pat_127	m	0	U	LP	1	1	0	1
Pat_128	m	0	M	HP	1	0	0	0
Pat_129	m	1	U	LP	1	0	0	0
Pat_130	f	0	M	IP	1	0	0	0
Pat_131	f	0	U	LP	1	0	0	1
Pat_132	m	1	U	LP	1	0	0	1
Pat_133	m	1	U	LP	1	0	0	1
Pat_134	m	1	M	HP	1	0	0	1
Pat_135	m	0	M	HP	1	0	0	0
Pat_136	m	0	M	HP	1	0	0	0
Pat_137	f	0	U	LP	0	0	1	0
Pat_138	f	0	M	HP	1	0	0	0
Pat_139	f	0	M	HP	NA	NA	NA	NA
Pat_140	f	0	M	IP	1	0	0	0
Pat_141	m	0	M	IP	1	0	0	0
Pat_142	m	0	M	HP	1	0	0	0
Pat_143	f	0	U	LP	1	0	0	0
Pat_144	m	1	U	LP	0	0	0	1
Pat_145	f	0	M	HP	0	0	0	0
Pat_146	m	1	U	LP	NA	NA	NA	NA
Pat_147	m	1	U	LP	0	0	0	1
Pat_148	m	1	U	NA	1	0	0	0
Pat_149	m	1	U	LP	0	1	1	0
Pat_150	f	0	M	HP	1	0	0	NA
Pat_151	m	0	U	LP	0	0	1	0
Pat_152	m	0	NA	NA	0	1	1	0
Pat_153	m	1	U	LP	1	0	0	0
Pat_154	m	0	M	HP	1	0	0	0
Pat_155	m	0	M	HP	1	0	0	0
Pat_156	f	0	U	LP	1	0	0	0
Pat_157	f	0	U	LP	1	1	0	0
Pat_158	m	0	M	HP	1	0	0	0
Pat_159	f	0	U	LP	1	0	0	0
Pat_160	m	0	U	LP	NA	NA	NA	NA
Pat_161	m	1	U	LP	0	0	0	0
Pat_162	m	0	M	HP	0	0	0	0
Pat_163	m	0	M	HP	0	0	0	0
Pat_164	f	0	U	LP	0	0	0	0
Pat_165	m	1	U	LP	0	1	1	0
Pat_166	m	0	U	LP	1	0	1	0
Pat_167	m	0	NA	IP	NA	NA	NA	NA
Pat_168	m	0	M	HP	1	1	0	0
Pat_169	m	0	M	HP	0	0	1	0
Pat_170	m	0	M	HP	1	0	0	0
Pat_171	m	0	M	HP	1	0	0	0
Pat_172	m	0	M	HP	1	0	0	0
Pat_173	m	0	M	HP	1	0	0	0
Pat_174	f	0	U	LP	NA	0	NA	0
Pat_175	m	0	U	LP	0	0	0	0
Pat_176	f	0	M	HP	NA	NA	NA	NA
Pat_177	f	0	NA	IP	NA	1	NA	NA
Pat_178	m	0	M	HP	1	0	0	0
Pat_179	m	0	U	LP	0	1	0	0
Pat_180	m	0	M	HP	NA	NA	NA	NA
Pat_181	f	0	M	HP	NA	NA	NA	NA

(continued)

Patient ID	Sex	Treated before	IGHV status	Methylation Cluster	Del13q	Del11q	Trisomy 12	Del17p
Pat_182	m	0	M	HP	1	0	0	0
Pat_183	f	1	NA	IP	1	0	0	0
Pat_184	m	0	U	LP	NA	NA	NA	NA
Pat_185	m	0	M	HP	NA	NA	NA	NA
Pat_186	m	0	M	HP	1	0	0	0
Pat_187	m	1	U	LP	NA	NA	NA	NA
Pat_188	m	0	NA	NA	NA	NA	NA	NA
Pat_189	m	0	NA	NA	NA	NA	NA	NA
Pat_190	m	0	NA	NA	NA	NA	NA	NA
Pat_191	f	0	NA	NA	0	0	0	0
Pat_192	f	0	NA	NA	1	0	0	0


Appendix Table 3. Patient samples included in the study. List of patient samples and selected characteristics. For a full list of characteristics see online vignette.

Factor	HR	p value	CI Low	CI High
Cluster 3 vs Cluster 1	0.95	0.87	0.53	1.72
Cluster 3 vs Cluster 2	1.56	0.26	0.72	3.41
Cluster 3 vs Cluster 4	0.35	0.02	0.14	0.87
IGHV.status	2.04	0.28	0.55	7.50
trisomy 12	0.99	0.98	0.48	2.07
TP53	4.12	<0.0001	2.42	7.02
Methylation_ClusterIP	1.47	0.37	0.63	3.42
Methylation_ClusterLP	0.93	0.92	0.23	3.74


Appendix Table 4. Multivariate survival analysis of response clusters. Multivariate Cox proportional hazards model of stimuli response clusters and genetic subgroups of disease progression using TTT and C3 as reference.

Factor	HR	p value	CI Low	CI High
Cluster 3 vs Cluster 1	1.27	0.37	0.75	2.16
Cluster 3 vs Cluster 2	2.06	0.03	1.07	3.93
Cluster 3 vs Cluster 4	0.35	0.01	0.17	0.73


Appendix Table 5. Survival analysis of microenvironmental response clusters comparing Cluster 3 to the other Clusters.





Appendix Figure 1. Genetic profiles of screened patient samples. Selected genetic alterations on y-axis and screened patient samples on x-axis.




Appendix Figure 3. Response to stimuli by IGHV status. Viability after 48h incubation with microenvironmental stimuli. Log transformed viabilities, normalized to DMSO solvent controls, stratified by IGHV status. BH-adjusted p-values are shown from one-sample t-tests of all patient samples. ($p < 0.00001$ = *****, $p < 0.0001$ = ****, $p > 0.05$ = ns)




Appendix Figure 4. Stimuli response by clusters. Log transformed viabilities after treatment with stimuli, faceted by cluster. BH-adjusted p-values from student's t-tests are shown.




Appendix Figure 5. Time to first treatment and overall survival by clusters. Kaplan-Meier Curves of time to first treatment with p-value from univariate Cox proportional hazards model between C3 and C4 (**A**) and overall survival with p-value from univariate Cox proportional hazards model between C1&2 and C3&4 (**B**). Median survival not reached.




Appendix Figure XX. Multinomial regression with lasso penalisation to identify enrichment or depletion of genetic features within each cluster.




Appendix Figure XXX. Methylation profile of Clusters defined by response to microenvironmental stimuli Barplot of methylation profiles in the four clusters of microenvironmental response. Predominantly IGHV unmutated clusters 1 and 2 show higher abundance of Low programmed Methylation profiles, while predominantly IGHV mutated clusters 3 and 4 show more highly programmed methylation clusters.




Appendix Figure XXX. CLL Proliferative Drive as defined by Lu et al., 2021⁵ Beeswarm Plot of Proliferative drive in the clusters defined by microenvironmental resonance. P-values are shown from student's t-tests.




Appendix Figure XXX. Drug response between clusters. Heatmap showing the log normalised viability after drug treatment. Rows represent drug treatments and columns represent primary CLL samples, annotated for their genetic background, sex and pretreatment status above. Red values indicate increased viability upon treatment, blue indicates decreased viability.



Appendix Figure 6. RNA-Sequencing of matched samples indicates differential gene expression between Cluster 3 and Cluster 4. Volcano plot of differentially expressed genes between Cluster 3 and Cluster 4 (**A**). X axis indicates log2 fold change values, calculated using the Deseq package, y axis gives corresponding $-\log_{10}(\text{adjusted p value})$. P values adjusted using BH method. Genes are labeled where p value < 0.05. Enrichment plots of selected pathways (**B-D**). Gene set enrichment analysis (GSEA) was performed with the Hallmark gene sets from the GSEA Molecular Signatures Database. Wald statistic was used to rank the genes. The green curve corresponds to the Enrichment Score curve, which is the running sum of the weighted enrichment score obtained from GSEA software.




Appendix Figure 7. Correlation of stimuli response and receptor expression. The effects of the microenvironmental stimuli on viability were largely independent of the expression of the corresponding stimuli receptors. Volcano plot depicts Pearson correlation coefficients against corresponding BH-adjusted p values, for the correlation between control - normalised log viability values with each stimulus and vst RNA counts of corresponding stimuli receptor. RNA counts taken from RNA-Sequencing of untreated matched CLL patient sample. Only viability after treatment with Resiquimod correlated with receptor expression ($R > 0.3$).




Appendix Figure 8. BCR inhibition by ibrutinib counters the protective effect of TLR stimulation in all genetic subgroups of IGHV and trisomy 12. Log normalized viability after treatment with resiquimod with and without ibrutinib. Faceted by IGHV mutation status and trisomy 12.

```
## Warning: ggrepel: 17 unlabeled data points (too many overlaps). Consider
## increasing max.overlaps
```



Appendix Figure 9. ATAC-Seq comparing trisomy 12 and non-trisomy 12 CLL samples. Volcano plot shows change in inferred TF activity (x axis) against adjusted p-values (y axis) for trisomy 12 ($n = 2$) versus non-trisomy 12 samples ($n = 2$). Inferred TF activity calculated using the diffTF package, and measured as weighted mean difference. p-values are obtained through diffTF in analytic mode and adjusted by the Benjamini-Hochberg procedure. TFs are labeled where absolute weighted mean difference > 0.15 , and adjusted p-value < 0.01 .


```
## Warning: ggrepel: 9 unlabeled data points (too many overlaps). Consider
## increasing max.overlaps
```




Appendix Figure 10. ATAC-Seq comparing trisomy 12 and non-trisomy 12 CLL samples, without including TF binding sites on chromosome 12. Volcano plot shows change in inferred TF activity (x axis) against adjusted p-values (y axis) for trisomy 12 (n = 2) versus non-trisomy 12 samples (n = 2). Inferred TF activity calculated using the diffTF package, and measured as weighted mean difference. p-values are obtained through diffTF in analytic mode and adjusted by the Benjamini-Hochberg procedure. TFs are labelled where absolute weighted mean difference > 0.15, and adjusted p-value < 0.01.

CELL CYCLE PATHWAYS	Reactome	507	100
SIGNALING BY INTERLEUKINS	Reactome	463	117
OF SIGNAL TRANSDUCTION BY GROWTH FACTOR RECEPTORS AND SECOND MESSENGERS	Reactome	394	93
RHO GTPASE EFFECTORS	Reactome	324	90
CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION	Reactome	377	89
TRANSCRIPTIONAL REGULATION BY TP53	Reactome	363	86
DNA REPAIR	Reactome	332	85
SIGNALING BY WNT	Reactome	331	79
SIGNALING BY ROBO RECEPTORS	Reactome	218	68
HIV INFECTION	Reactome	231	68
APOPTOSIS	KEGG	234	65
TRANSCRIPTIONAL REGULATION BY RUNX1	Reactome	239	63
TOLL LIKE RECEPTOR CASCADES	Reactome	155	56
REGULATION OF EXPRESSION OF SLITS AND ROBOS	Reactome	172	56
RAC1 GTPASE CYCLE	Reactome	184	56
SUMOYLATION	Reactome	187	56
RRNA PROCESSING	Reactome	205	56
REGULATION OF ACTIN CYTOSKELETON	KEGG	213	56
PROGRAMMED CELL DEATH	Reactome	208	54
INFLUENZA INFECTION	Reactome	157	51
CHEMOKINE SIGNALING PATHWAY	KEGG	189	50
ENDOCYTOSIS	KEGG	181	49


Appendix Figure 11. Over-representation tests of all KEGG and Reactome pathways in ChIPseq analysis of Spi-B binding in lymphoma cell lines



Appendix Figure 12. Genetic predictors of drug - stimulus interactions. Heatmap depicting overview of genetic predictors of drug - stimulus interactions (each row represents the coefficients from fitting a single multivariate model). Stimuli are shown on left, and corresponding drugs on right. Drugs, stimuli and genetic alterations are alphabetically sorted. Coloured fields indicate that the β_{int} for given drug and stimulus is modulated by corresponding genetic feature. Positive coefficients are shown in red, indicating β_{int} is more positive for given drug and stimulus combination if the feature is present.



Appendix Figure 13. Genetic predictors of the interaction between ibrutinib and IL4. Predictor profile depicting genetic features that modulate the size of β_{int} for ibrutinib and IL4. To generate predictor profile, linear model in Eqn. (1) was fitted in a sample - specific manner, to calculate drug-stimulus interaction coefficients (β_{int}) for each patient sample. Ranked patient-specific β_{int} values are shown in lower scatter plot. Associations between the size of β_{int} and genetic features were identified using multivariate regression with L1 (lasso) regularisation, with gene mutations and IGHV status as predictors, and selecting coefficients that were chosen in >90% of bootstrapped model fits. The horizontal bars on left show the size of fitted coefficients assigned to genetic features. Matrix above scatter plot indicates patient mutation status for the selected genetic features. Matrix fields correspond to points in scatter plot (ie patient data is aligned), to indicate how the size of β_{int} varies with selected genetic feature.



Appendix Figure 14. STAT6 dependency of IL4 signaling. The effects observed with IL4 stimulation are dependent on STAT6 activation. Addition of the STAT6 inhibitor AS1517499 could revoke the effect on baseline viability as well as drug induced toxicity. Log transformed viability after treatment with IL4 in combination with ibrutinib, the STAT6 inhibitor AS1517499, and both.

References

1. Dietrich S, Oleś M, Lu J, et al. Drug-perturbation-based stratification of blood cancer. *J. Clin. Invest.* 2018;128(1):427–445.
2. Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. *Curr. Protoc. Mol. Biol.* 2015;109:21.29.1–21.29.9.
3. Berest I, Arnold C, Reyes-Palomares A, et al. Quantification of Differential Transcription Factor Activity and Multiomics-Based Classification into Activators and Repressors: diffTF. *Cell Rep.* 2019;29(10):3147–3159.e12.
4. Kulakovskiy IV, Vorontsov IE, Yevshin IS, et al. HOCOMOCO: expansion and enhancement of the collection of transcription factor binding sites models. *Nucleic Acids Res.* 2016;44(D1):D116–25.
5. Lu, J., Cannizzaro, E., Meier-Abt, F. et al. Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. *Nat Cancer* 2, 853–864 (2021).